HemeScan is a bacterial artificial chromosome array designed to identify known prognostic genomic imbalances relevant to the clinical course of chronic lymphocytic leukemia, according to CMBX. The company said it anticipates launching other array CGH-based oncology diagnostics and prognostics in coming months.
Sigma-Aldrich last week launched its Panorama antibody microarray XPRESS Profiler725, a high-throughput tool for multiplex profiling of protein expression in serum, cell, or tissue extracts.
According to Sigma, the Panorama XPRESS Profiler725 contains 725 antibodies arrayed in duplicate on nitrocellulose slides and is compatible with most DNA array scanners. The arrayed antibodies detect human, mouse, and rat proteins associated with a variety of key cell signaling and gene regulation pathways. The array includes subsets of antibodies targeted to the mitogen-activated protein kinase,, protein kinase C, and p53 protein families.
CombiMatrix said this week that its CombiMatrix Molecular Diagnostics subsidiary has launched the second version of its Constitutional Genetic Array Test (CA850).
The test utilizes the company’s new bacterial artificial chromosome array, which includes over 200 new, validated probes obtained through the company’s partnership with the Center for Applied Genomics, in Toronto.
The CA850, which can identify over 50 common genetic disorders in one test, has now been clinically validated for use in both postnatal and prenatal analyses by CMDX, the company said.
Last week CMDX also announced that it is now offering HemeScan, an array comparative genomic hybridization assay designed to detect prognostic markers in chronic lymphocytic leukemia. The test is now available to the clinical community through both routine clinical sample processing as well as through CMDX's Technical Only Program for reference laboratories, CMBX said.